IP
ONCT

Intellectus Partners’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Intellectus Partners’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,650
Closed -$162K – 267
2020
Q4 		$162K Buy
+1,650
New +$104K 0.05% 223

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return

Intellectus Partners's ONCT Position: Q1 2021 in Review

Intellectus Partners sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2021, closing a stake of 1,650 shares — an estimated $162K sold.

Intellectus Partners first reported a position in ONCT in Q4 2020 and held it in 1 quarter. The position peaked at $162K in Q4 2020. 64 funds tracked by Wall St. Rank hold ONCT as of Q1 2021.

  • Intellectus Partners reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Intellectus Partners sold 1,650 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $162K.
  • Intellectus Partners first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Intellectus Partners's Oncternal Therapeutics, Inc. Common Stock position peaked at $162K in Q4 2020.
  • 64 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Intellectus Partners's 13F filing for Q1 2021, filed 17 May 2021.